Significance of multidisciplinary therapy for hepatocellular carcinoma
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 31 (S1) , S13-S19
- https://doi.org/10.1007/bf00687098
Abstract
Summary The effect of multidisciplinary therapy for hepatocellular carcinoma (HCC) was evaluated in 121 resected cases. The 5-year survival was 100% for absolute curative resection (12 cases), 59.1% for relative curative resection (n-37) and 10.9% for relative non-curative resection (n=59). However, none of the patients survived for more than 3 years after absolute non-curative resection (n-13). The non-recurrence in the preoperative TAE groups was different from that in non-TAE groups under-going absolute and relative curative resection. The 1- and 3-year non-recurrence rates for relative non-curative resection were 92.3% and 53.8%, respectively, for the preoperative TAE group and 56.1% and 28.1%, respectively for the non-TAE group. These data show that preoperative TAE is effective in relative non-curative resection. Functional disturbances of the coagulation-fibrinolysis system in cirrhotic patients were improved after PSE. All patients undergoing hepatectomy after PSE had an uneventful postoperative course, including well-maintained function of the coagulation-fibrinolysis system and a decrease in splenic volume. At 1 year after hepatectomy, cirrhotic patients with critical liver function and poor coagulation-fibrinolysis showed appreciable hepatic regeneration. One patients died of hepatic failure 1 year after the operation. In recurrent HCC, the 1-, 2- and 3-year survivial values after reresection were 100%, 75.0% and 25.0%, respectively. The respective values following TAE were 79.0%, 42.0% and 9.0%. Three cases of recurrent HCC were effectively treated, i.e., two patients achieved a partial response and one showed no change, by continuous intra-arterial infusion of 5-FU and lentinan with intermittent one-shot injections of epirubicin using a subcutaneous infusion pump. These three patients are alive at 1 year and 7 months, 1 year and 4 months and 6 months after the treatment, respectively.Keywords
This publication has 14 references indexed in Scilit:
- Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patientsJournal of Gastroenterology and Hepatology, 1990
- Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.American Journal of Roentgenology, 1990
- Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinomaHepatology, 1989
- The general rules for the clinical and pathological study of primary liver cancerSurgery Today, 1989
- A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinomaCancer Chemotherapy and Pharmacology, 1989
- Primary liver cancer in Japan. Sixth reportCancer, 1987
- Second hepatic resection for recurrent hepatocellular carcinomaBritish Journal of Surgery, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Selective effects of lipiodolized antitumor agentsJournal of Surgical Oncology, 1984
- Preoperative estimation of operative risk in liver surgery, with special reference to functional reserve of the remnant liver following major hepatic resectionSurgery Today, 1979